These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8765031)

  • 1. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
    Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
    Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
    Yang G; Hellström KE; Hellström I; Chen L
    J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.
    Matulonis U; Dosiou C; Freeman G; Lamont C; Mauch P; Nadler LM; Griffin JD
    J Immunol; 1996 Feb; 156(3):1126-31. PubMed ID: 8557988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
    Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules.
    Liu Y; Wang H; Zhao J; Ma J; Wei L; Wu S; Xie T; Shen F; Trojan J; Habib N; Anthony DD; Wu M; Guo Y
    Cancer Gene Ther; 2000 Mar; 7(3):456-65. PubMed ID: 10766352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogene therapy against mouse leukemia using B7 molecules.
    Takahashi T; Hirano N; Takahashi T; Chiba S; Yazaki Y; Hirai H
    Cancer Gene Ther; 2000 Jan; 7(1):144-50. PubMed ID: 10678367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
    Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
    Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T
    Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
    J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J; Chen Y; Moyana T
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
    Guinn BA; Bertram EM; DeBenedette MA; Berinstein NL; Watts TH
    Cell Immunol; 2001 May; 210(1):56-65. PubMed ID: 11485353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.